Webb12 maj 2024 · The theranostic concept of PCa based on prostate-specific membrane antigen (PSMA) overexpression, led to the use of PSMA ligands for systemic therapy in patients with metastatic PC. PSMA has emerged as an attractive diagnostics PCa and therapeutic target for small molecule ligands in prostate cancer. Webb[68Ga]Ga-PSMA-11 PET/CT plays a pivotal role in the diagnosis and staging of prostate cancer because of its higher sensitivity and detection rate compared with traditional choline PET/CT. A highly reproducible radiochemical yield of the radiopharmaceutical to be used in the clinical routine is an important parameter for planning and optimization of …
Theranostics - Definition and Treatment GenesisCare AU
WebbTheranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment. Theranostics uses PET scan imaging (a special … WebbPSMA levels are tightly linked to the androgen recep- tor pathway, and they increase as resistance to hormonal ... -term follow-up and outcomes of retreatment in an expanded … how many people work 3rd shift
The History of Prostate-Specific Membrane Antigen as a …
Webb29 apr. 2024 · For PSMA theranostics, post-therapeutic dosimetry may be a useful tool to tailor the treatment protocol to a patient’s individual needs, e.g., by providing absorbed … WebbGCPII also known as Prostate Specific Membrane Antigen (PSMA), is overexpressed in prostate cancer (PCa) cells and provide a biomarker for tumor targeting PSMA receptor. The development of lysine-urea-glutamate pharmacophore based inhibitors targeting PSMA for theranostics applications led to PSMA11 and PSMA617. WebbFör 1 dag sedan · ![Figure][1] Wolfgang A. Weber The term theranostics has clearly become a buzzword. To a large extent, this is due to the success of prostate-specific membrane antigen (PSMA)–targeted radioligands. These ligands can be labeled with positron- or γ-emitting isotopes for imaging or with how can you tell the diff